PDS Biotechnology proposes 1-for-10–1-for-35 reverse split
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
PDS Biotechnology Corporation (PDSB) is seeking approval for a 1-for-10 to 1-for-35 reverse stock split through a charter amendment. If stockholders approve, the Board would decide whether to implement it, select the ratio, and could act on or before December 31, 2027; approval does not require the Board to proceed.
PDSB had not regained compliance with Nasdaq’s $1.00 minimum bid-price requirement, which requires the closing bid price to be at least $1.00 for 10 consecutive business days. The stock closed at $0.8073 on November 19, 2026, and the initial 180-calendar-day compliance period ends January 26, 2027. If compliance is not regained, PDSB may be eligible for an additional 180-day period subject to conditions, or Nasdaq may commence delisting proceedings. The company says a reverse split may not sustain a higher share price or ensure continued listing. 114,856,548 common shares were outstanding as of November 20, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Nasdaq’s $1.00 minimum-bid-price deficiency remains unresolved: PDSB’s stock closed at $0.8073 on November 19, 2026, and the initial compliance period ends January 26, 2027. Failure to regain compliance could lead to delisting proceedings.
Filing Explained
If implemented, the split would preserve holders’ percentage ownership except for fractional-share cash-outs, but leave 300 million authorized shares while expanding unissued, unreserved shares from 123,047,504 to 282,304,753–294,944,217. Later issuance could dilute holders, though no specific issuance plans are disclosed.
Key Figures
Key Terms
minimum bid price requirement regulatory
authorized but unissued shares financial
broker non-votes regulatory
fractional shares financial
recapitalization financial
backup withholding financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What reverse stock split ratio is PDSB asking stockholders to approve?
Why is PDSB proposing a reverse stock split?
Would PDSB’s reverse split reduce its authorized common shares?
How would PDSB handle fractional shares in a reverse split?
How many votes are needed to approve PDSB’s reverse split proposal?
AI-generated analysis. How Rhea-AI works. Not financial advice.
TABLE OF CONTENTS
☒ | Preliminary Proxy Statement |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material under §240.14a-12 |
PDS BIOTECHNOLOGY CORPORATION |
(Name of Registrant as Specified In Its Charter) |
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
☒ | No fee required. |
☐ | Fee paid previously with preliminary materials. |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
TABLE OF CONTENTS
1. | To approve an amendment to our Eighth Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect, in the sole discretion of the Board of Directors of the Company (the “Board”) at any time on or before December 31, 2027, a reverse stock split of the Company’s common stock, par value $0.00033 per share (the “Common Stock”), at a ratio to be determined by the Board within a range of 1-for-10 to 1-for-35 (or any whole number in between), without reducing the authorized number of shares of the Common Stock, and without further approval or authorization of our stockholders (the “Reverse Stock Split Proposal”); and |
2. | To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”). |
By Order of the Board of Directors | |||
Chief Executive Officer | |||
TABLE OF CONTENTS
Page | |||
About the Special Meeting | 1 | ||
Proposal No. 1 — Reverse Stock Split Proposal | 7 | ||
Proposal No. 2 — Adjournment Proposal | 16 | ||
Security Ownership of Certain Beneficial Owners and Management | 17 | ||
Householding of Proxy Materials | 18 | ||
Where You Can Find Additional Information | 19 | ||
Other Matters | 20 | ||
Appendix A - Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation | A-1 | ||
TABLE OF CONTENTS
• | This Proxy Statement for the Special Meeting; |
• | The proxy card or a voting instruction form for the Special Meeting. |
TABLE OF CONTENTS
Proposal 1: | To approve an amendment to the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect, in the sole discretion of the Board at any time on or before December 31, 2027, a reverse stock split of the Common Stock, at a ratio to be determined by the Board within a range of 1-for-10 to 1-for-35 (or any whole number in between), without reducing the authorized number of shares of the Common Stock, and without further approval or authorization of our stockholders (the “Reverse Stock Split Proposal”); and |
Proposal 2: | To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”). |
TABLE OF CONTENTS
• | Via Webcast: You may attend the Special Meeting via the internet and vote during the Special Meeting. The Special Meeting can be accessed by visiting www.virtualshareholdermeeting.com/PDSB2026SM and entering your 16-digit control number which is included on your proxy card. Please have your proxy card in hand when you access the website and then follow the instructions. |
• | By Mail: You may vote by proxy by filling out the proxy card you received and returning it promptly in the envelope provided. If you return your signed proxy card to us before the Special Meeting, we will vote your shares as you direct. |
• | By Telephone: To vote over the telephone, dial toll-free (800) 690-6903 using a touch-tone phone and follow the recorded instructions. Have your 16-digit control number available when you call. You will be asked to provide the company number and control number from your proxy card. Your telephone vote must be received by 11:59 p.m., Eastern Time on December [ ], 2026 to be counted. |
TABLE OF CONTENTS
• | Via the Internet: To vote through the internet before the Special Meeting, go to www.proxyvote.com and follow the on-screen instructions. Please have your 16-digit control number found on your proxy card or voting instruction form in hand when you access the website and then follow the instructions. Your internet vote must be received by 11:59 p.m., Eastern Time on December [ ], 2026 to be counted. |
• | “For” the Reverse Stock Split Proposal; and |
• | “For” the Adjournment Proposal. |
TABLE OF CONTENTS
• | You may submit another properly completed proxy card with a later date. |
• | You may grant a subsequent proxy by telephone or through the internet. |
• | You may send a timely written notice that you are revoking your proxy to our Secretary at PDS Biotechnology Corporation at 303A College Road East, Princeton, NJ 08540. |
• | You may attend the Special Meeting via the internet and vote online at the meeting. Simply attending the Special Meeting will not, by itself, revoke your proxy. |
• | Proposal No. 1 – The approval of the Reverse Stock Split Proposal requires the affirmative vote of a majority of the votes cast on this proposal at the Special Meeting, in accordance with Section 242(d)(2) of the General Corporation Law of the State of Delaware (the “DGCL”). Stockholder abstentions are not considered votes cast and thus will have no effect on the outcome of this proposal. Because this proposal is considered a “routine” matter, brokers will have discretionary authority to vote on this proposal and broker non-votes are not expected. |
• | Proposal No. 2 – The approval of the Adjournment Proposal requires the affirmative vote of the majority of the shares of our Common Stock present in person or by remote communication, if applicable, or represented by proxy at the Special Meeting and entitled to vote thereon. Stockholder abstentions are considered shares present and entitled to vote on this proposal, and thus, will have the same effect as a vote “Against” this proposal. Broker non-votes will have no effect on the outcome of this proposal. |
TABLE OF CONTENTS
TABLE OF CONTENTS
1. | Maintain our listing on the Nasdaq Capital Market. Our Common Stock is traded on the Nasdaq Capital Market. On July 30, 2026, we received a notice from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Common Stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided an initial period of 180 calendar days, or until January 26, 2027, to regain compliance with the minimum bid price requirement. |
TABLE OF CONTENTS
TABLE OF CONTENTS
2. | Stock Price Volatility. We understand that a higher stock price may increase the acceptability of the Common Stock to investors who may not find shares of Common Stock attractive at the current market price due to the trading volatility often associated with stocks below certain prices. |
3. | Transaction Costs. Investors also may be dissuaded from purchasing stocks below certain prices because the brokerage commissions, as a percentage of the total transaction value, tend to be higher for such low-priced stocks. |
4. | Stock Price Requirements. We understand that many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers or by restricting or limiting the ability to purchase such stocks on margin. |
• | our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; |
• | the per share price of the Common Stock immediately prior to the Reverse Stock Split; |
• | the expected stability of the per share price of the Common Stock following the Reverse Stock Split; |
• | the likelihood that the Reverse Stock Split will result in increased marketability and liquidity of the Common Stock; |
• | the anticipated impact of the Reverse Stock Split on our ability to raise additional financing; |
• | which split ratio would result in the greatest overall reduction in our administrative costs; |
• | general economic conditions in our industry; and |
• | our market capitalization before and after the Reverse Stock Split. |
TABLE OF CONTENTS
TABLE OF CONTENTS
Pre-Reverse Stock Split | Post-Reverse Stock Split | |||||||||||
10:1 | 25:1 | 35:1 | ||||||||||
Authorized | 300,000,000 | 300,000,000 | 300,000,000 | 300,000,000 | ||||||||
Outstanding | 114,856,548 | 11,485,654 | 4,594,261 | 3,281,615 | ||||||||
Reserved for issuance upon issuance of common stock warrants | 19,016,707 | 1,901,670 | 760,668 | 543,334 | ||||||||
Reserved for issuance upon exercise of pre-funded warrants | 31,346,152 | 3,134,615 | 1,253,846 | 895,604 | ||||||||
Reserved for future issuance pursuant to the outstanding options and restricted stock units | 10,107,211 | 1,010,721 | 404,288 | 288,777 | ||||||||
Reserved for future issuance pursuant to the Equity Plans | 1,625,878 | 162,587 | 65,035 | 46,453 | ||||||||
Authorized but unissued and unreserved | 123,047,504 | 282,304,753 | 292,921,902 | 294,944,217 | ||||||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Beneficial Ownership | ||||||
Name of Beneficial Owner | Shares | %(1) | ||||
Greater than 5% Stockholders: | ||||||
Nant Capital, LLC(2) | 22,856,453 | 19.9% | ||||
PDS Biotech Named Executive Officers and Directors: | ||||||
Frank Bedu-Addo, Ph.D.(3) | 5,649,806 | 4.7% | ||||
Patrick Soon-Shiong, M.D.(2) | 22,856,453 | 19.9% | ||||
James Banaag | — | — | ||||
John Dawson CBE | — | — | ||||
Ilian Iliev, Ph.D.(4) | 65,074 | * | ||||
Deborah Ramsdell | — | — | ||||
Bruce Wendel | — | — | ||||
Kirk Shephard(5) | 286,815 | * | ||||
Stephan Toutain(6) | — | — | ||||
All current executive officers and directors as a group (10 persons)(7) | 29,923,829 | 24.7% | ||||
* | Less than 1% |
(1) | Percentage ownership is based on 114,856,548 shares of common stock outstanding as of the Record Date, together with securities exercisable or convertible into shares of common stock within 60 days of such date for each stockholder. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. |
(2) | Consists of 22,856,453 shares of common stock held by Nant Capital, LLC, over which Nant Capital, LLC has sole voting and dispositive power. Dr. Patrick Soon-Shiong, a member of our Board, is the sole member of Nant Capital, LLC and may be deemed to beneficially own the shares held by Nant Capital, LLC . Dr. Soon-Shiong was appointed to the Board effective September 14, 2026 as a designee of Nant Capital, LLC pursuant to a securities purchase agreement, dated September 7, 2026, in connection with the Company’s private placement transaction. Excludes 30,240,892 shares issuable upon exercise of pre-funded warrants held by Nant Capital, LLC, which are subject to an exercise limitation prohibiting exercise to the extent the holder would beneficially own more than 19.9% of the outstanding common stock (which limitation may be adjusted upon 61 days’ notice, but not above 19.99%). The address of Nant Capital, LLC is 450 Duley Road, El Segundo, CA 90245. Information in this footnote regarding the holdings of Nant Capital, LLC is based on Amendment No. 1 to Schedule 13D jointly filed by Nant Capital, LLC and Dr. Soon-Shiong with the SEC on November 12, 2026. |
(3) | Includes 690,866 shares of common stock and 4,958,940 shares subject to outstanding options exercisable within 60 days of the Record Date. |
(4) | Includes 65,074 shares subject to outstanding options exercisable within 60 days of the Record Date. |
(5) | Includes 286,815 shares subject to outstanding options exercisable within 60 days of the Record Date. |
(6) | Mr. Toutain ceased serving as the Company’s Chief Operating Officer effective August 21, 2026, and is no longer employed by the Company. |
(7) | Includes 6,252,921 shares subject to outstanding options exercisable within 60 days of the Record Date. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
PDS BIOTECHNOLOGY CORPORATION | ||||||
By: | ||||||
Name: | Frank Bedu-Addo, Ph.D. | |||||
Title: | President and Chief Executive Officer | |||||
* | This amendment approves the combination of any whole number of shares of Common Stock between and including 10 and 35 into one (1) share of Common Stock. By approving this amendment, the stockholders would approve each of the alternative amendments proposed. |
TABLE OF CONTENTS

TABLE OF CONTENTS
